N

Neuro-Behavioral Clinical Research | North Canton, OH

Research site
(Unclaimed)
Location
5080 Aultman Avenue NW, North Canton, Ohio, United States of America

Site insights

Top conditions

Top treatments

KarXT
fezolinetant
Simufilam
SEP-4199
BI 1569912
Belviq XR®
PCN-101
Quetiapine XR
Iclepertin
PTI-125

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 22 total trials

A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to plac...

Enrolling
Sickle Cell Disease
Drug: Placebo Tablets
Drug: Etavopivat Tablets High dose

This study is open to adults between 18 and 65 with a type of depression (major depressive disorder) for whom previous treatments for depression did...

Enrolling
Depressive Disorder, Major
Drug: BI 1569912
Drug: Placebo
Locations recently updated

This is a Phase 3, multicenter, 56-week, outpatient, open-label (OL) study to evaluate the long-term safety, tolerability, and efficacy of KarXT in d...

Active, not recruiting
Schizophrenia
Drug: Xanomeline and Trospium Chloride Capsules

This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning. Example...

Active, not recruiting
Schizophrenia
Drug: Iclepertin
Drug: Placebo

The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in chil...

Enrolling
Pediatric Migraine
Drug: Rimegepant/BHV3000
Drug: Matching placebo

This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult...

Enrolling
Schizophrenia
Drug: LB-102

A 76-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 76 we...

Active, not recruiting
Alzheimer Disease
Drug: Placebo
Drug: Simufilam

Trial sponsors

Boehringer Ingelheim logo
Sumitomo Pharma logo
Astellas logo
C
Karuna Therapeutics logo
Pfizer logo
Eisai logo
Forma Therapeutics logo
G
Janssen (J&J Innovative Medicine) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems